BRPI0412820A - compostos de aminopirazol e utilização como inibidores de chk1 - Google Patents

compostos de aminopirazol e utilização como inibidores de chk1

Info

Publication number
BRPI0412820A
BRPI0412820A BRPI0412820-6A BRPI0412820A BRPI0412820A BR PI0412820 A BRPI0412820 A BR PI0412820A BR PI0412820 A BRPI0412820 A BR PI0412820A BR PI0412820 A BRPI0412820 A BR PI0412820A
Authority
BR
Brazil
Prior art keywords
compounds
aminopyrazole
chk1 inhibitors
methods
aminopyrazole compounds
Prior art date
Application number
BRPI0412820-6A
Other languages
English (en)
Inventor
Michael David Johnson
Min Teng
Jinjiang Zhu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0412820A publication Critical patent/BRPI0412820A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE AMINOPIRAZOL E UTILIZAçãO COMO INIBIDORES DE CHK1". São aqui descritos compostos de aminopirazol de fórmula (I): em que R¬ 1¬, R¬ 2¬, L e Ar são como definido na especificação. Estes compostos são capazes de modular a atividade de um ponto de controle de kinase e métodos para utilizar esta modulação para tratar distúrbios de células proliferativas. são também descritas composições farmacêuticas contendo estes compostos. é também descrita a utilização terapêutica ou profilática destes compostos e composições, e métodos de tratamento de câncer, assim como outras doenças associadas com a proliferação celular indesejada, por administração de quantidades eficazes destes compostos em combinação com agentes anti-neoplásicos.
BRPI0412820-6A 2003-07-25 2004-07-14 compostos de aminopirazol e utilização como inibidores de chk1 BRPI0412820A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48997603P 2003-07-25 2003-07-25
PCT/IB2004/002397 WO2005009435A1 (en) 2003-07-25 2004-07-14 Aminopyrazole compounds and use as chk1 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0412820A true BRPI0412820A (pt) 2006-09-26

Family

ID=34102954

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412820-6A BRPI0412820A (pt) 2003-07-25 2004-07-14 compostos de aminopirazol e utilização como inibidores de chk1

Country Status (6)

Country Link
US (1) US20050043381A1 (pt)
JP (1) JP2006528661A (pt)
BR (1) BRPI0412820A (pt)
CA (1) CA2532231A1 (pt)
MX (1) MXPA06000933A (pt)
WO (1) WO2005009435A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
WO2007002563A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
CN101248049B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 咪唑类lxr调节剂
DE102005035741A1 (de) * 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
WO2009099601A2 (en) * 2008-02-04 2009-08-13 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
PA8850801A1 (es) 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
JO3145B1 (ar) 2010-11-08 2017-09-20 Lilly Co Eli مركبات مفيدة لتثبيط chk1
WO2013091836A1 (en) * 2011-12-19 2013-06-27 Saudi Basic Industries Corporation (Sabic) Process for the preparation of metallocene complexes
CN104080792A (zh) * 2011-12-19 2014-10-01 沙特基础工业公司 用于制备茂金属络合物的方法
CN103275010A (zh) * 2013-05-30 2013-09-04 上海皓元生物医药科技有限公司 一种1-(3-甲基-1-苯基-1h-吡唑-5-基)哌嗪的制备方法
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
CN108601781B (zh) 2016-02-04 2019-11-22 广州必贝特医药技术有限公司 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
JP2019513700A (ja) 2016-03-16 2019-05-30 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺有害生物剤及び植物保護剤としてのｎ−（シアノベンジル）−６−（シクロプロピル−カルボニルアミノ）−４−（フェニル）−ピリジン−２−カルボキサミド誘導体及び関連する化合物
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
EP3284739A1 (de) 2017-07-19 2018-02-21 Bayer CropScience Aktiengesellschaft Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3749648B1 (en) 2018-02-07 2024-10-30 Korea Research Institute of Chemical Technology N-(phenyl)-5-(phenyl)-1h-pyrazol-3-amine derivatives as tnik inhibitors for use in the treatment of cancer
SG11202010068VA (en) 2018-04-25 2020-11-27 Bayer Ag Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
CN111072652B (zh) * 2018-10-19 2023-05-23 暨南大学 用于治疗糖尿病和/或相关病症的化合物
EP3867227A4 (en) * 2018-10-19 2022-08-03 Auckland Uniservices Limited COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR RELATED DISEASES
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
TW202136248A (zh) 2019-11-25 2021-10-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
CN114746413B (zh) 2019-11-29 2024-02-23 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
WO2021203014A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
EP4126863A1 (en) 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated 1 h-pyrazolo[4,3-g]isoquinoline and 1 h-pyrazolo[4,3-g]quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
TWI891782B (zh) 2020-05-06 2025-08-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基三唑化合物
US20240254121A1 (en) 2021-05-06 2024-08-01 Bayer Aktiengesellschaft Alkylamide substituted, annulated imidazoles and use thereof as insecticides
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
WO2023025682A1 (en) 2021-08-25 2023-03-02 Bayer Aktiengesellschaft Novel pyrazinyl-triazole compounds as pesticides
EP4455134A4 (en) * 2021-12-24 2025-10-08 Sumitomo Pharma Co Ltd 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON
WO2023226658A1 (en) * 2022-05-25 2023-11-30 Sperogenix Therapeutics Limited Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof
WO2025186065A1 (en) 2024-03-05 2025-09-12 Bayer Aktiengesellschaft Heteroaryl-substituted (aza)quinoxaline derivatives as pesticides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69532817T2 (de) * 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
US6235769B1 (en) * 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
HK1045507A1 (zh) * 1999-08-12 2002-11-29 Vertex Pharmaceuticals Incorporated C-jun n-末端激酶(jnk)及其他蛋白质激酶的抑制物
BR0110302A (pt) * 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
NZ523656A (en) * 2000-08-31 2004-11-26 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors

Also Published As

Publication number Publication date
WO2005009435A1 (en) 2005-02-03
US20050043381A1 (en) 2005-02-24
CA2532231A1 (en) 2005-02-03
JP2006528661A (ja) 2006-12-21
MXPA06000933A (es) 2006-03-30

Similar Documents

Publication Publication Date Title
MXPA06000933A (es) Compuestos de aminopirazol y uso como inhibidores de chk1.
BRPI0413580A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp
WO2003093297A3 (en) Protein kinase modulators and methods of use
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BRPI0408990A (pt) derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase
BRPI0413582A (pt) compostos, composições e métodos para inibir a atividade de proteasome
BRPI0510663A (pt) pelo menos uma entidade quìmica, composição, métodos para modular atividade da cinesina cenp-e, para inibir cenp-e, e para tratar uma doença proliferativa celular, e, uso de pelo menos uma entidade quìmica
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
MY157944A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associat ed with angiogenesis
MXPA06001193A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular.
BRPI0517921A (pt) métodos para preparar compostos de indazol
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0411868A (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
BRPI0515582A (pt) 3-(2-hidroxifenil)pirazóis e seu uso como moduladores de hsp90
BRPI0409926A (pt) saposina c-dops: um agente antitumor
BRPI0409263A (pt) composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
BRPI0406596A (pt) Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired